Letter to the Editor

Cancer Invest. 2021 Feb;39(2):202-203. doi: 10.1080/07357907.2020.1841219. Epub 2020 Nov 2.

Authors

Yousef Abu-Salha¹, Richard S Matulewicz², Marc A Bjurlin^{1

3}

Affiliations

¹ Department of Urology, University of North Carolina, Chapel Hill, North Carolina, USA.
² Departments of Urology and Population Health, NYU Grossman School of Medicine, New York, New York.
³ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.

PMID: 33089734
DOI: 10.1080/07357907.2020.1841219

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use
Cancer Survivors*
Humans
Male
Neoadjuvant Therapy / methods
Neoplasm Recurrence, Local / etiology*
Prostatectomy / methods
Prostatic Neoplasms / therapy*
Smoking / adverse effects*

Substances

Antineoplastic Agents, Hormonal